Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR3409-1
- Development stage
- Unknown
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BR3409-1 is an investigational small molecule drug developed by Boryung Corp. It is being studied as a treatment for type 2 diabetes mellitus and other metabolic diseases. The compound is part of the broader BR3409 program, which includes related formulations such as BR3409 and BR3409-2. Clinical trials have focused on evaluating the pharmacokinetics and safety of both single-agent administration and co-administration with related compounds in healthy volunteers under fasting and fed conditions. As of mid-2025, development remains in Phase 1 clinical trials, with no detailed public information available regarding its precise mechanism of action or molecular target[1][2].
- Other names
- BR3409-1BR-3409-1BR 3409-1
Beyond the preview
Go deeper on BR3409-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR3409-1.